Liquidia and Pharmosa Biopharm Expand Collaboration to Develop Sustained Release Inhaled Treprostinil (L606)
Liquidia Corp(LQDA) GlobeNewswire News Room·2024-10-02 18:00
Liquidia amends exclusive license to include key markets in Europe, Japan and elsewhere Liquidia also obtains rights to Pharmosa's next-generation nebulizers for use with L606 Pharmosa to receive $3.5 million upfront and up to $157.75 million in additional development and sales milestones tied to commercial sales outside of North America MORRISVILLE, N.C., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare ...